"EPI 001"[nm] - Search Results

Year	Number of Results
2010	1
2012	1
2013	1
2015	1
2016	1
2017	1
2018	1
2019	1
2022	2
2023	1
2024	0

1

EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor.

De Mol E, Fenwick RB, Phang CT, Buzón V, Szulc E, de la Fuente A, Escobedo A, García J, Bertoncini CW, Estébanez-Perpiñá E, McEwan IJ, Riera A, Salvatella X. De Mol E, et al. ACS Chem Biol. 2016 Sep 16;11(9):2499-505. doi: 10.1021/acschembio.6b00182. Epub 2016 Jul 14. ACS Chem Biol. 2016. PMID: 27356095 Free PMC article.

2

Amelioration of Hepatic Steatosis by the Androgen Receptor Inhibitor EPI-001 in Mice and Human Hepatic Cells Is Associated with the Inhibition of CYP2E1.

Wang S, Li X, Xu W, Gao J, Wang Y, Jia X, Li G, Pan Q, Chen K. Wang S, et al. Int J Mol Sci. 2022 Dec 16;23(24):16063. doi: 10.3390/ijms232416063. Int J Mol Sci. 2022. PMID: 36555703 Free PMC article.

3

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance.

Nicolescu RCB, Maylin ZR, Pérez-Areales FJ, Iegre J, Pandha HS, Asim M, Spring DR. Nicolescu RCB, et al. ChemMedChem. 2023 Jan 17;18(2):e202200548. doi: 10.1002/cmdc.202200548. Epub 2022 Nov 15. ChemMedChem. 2023. PMID: 36300876 Free PMC article.

4

EPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancer.

Brand LJ, Olson ME, Ravindranathan P, Guo H, Kempema AM, Andrews TE, Chen X, Raj GV, Harki DA, Dehm SM. Brand LJ, et al. Oncotarget. 2015 Feb 28;6(6):3811-24. doi: 10.18632/oncotarget.2924. Oncotarget. 2015. PMID: 25669987 Free PMC article.

5

Successful micronucleus testing with the EPI/001 3D reconstructed epidermis model: preliminary findings.

Andres E, Molinari J, Remoué N, Sá-Rocha VM, Barrichello C, Hurtado SP. Andres E, et al. Mutat Res. 2012 Mar 18;743(1-2):36-41. doi: 10.1016/j.mrgentox.2011.12.026. Epub 2012 Jan 14. Mutat Res. 2012. PMID: 22266475

6

Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCaP prostate cancer cells.

Cha S, Shin DH, Seok JR, Myung JK. Cha S, et al. Exp Cell Res. 2017 Oct 1;359(1):215-225. doi: 10.1016/j.yexcr.2017.07.026. Epub 2017 Jul 20. Exp Cell Res. 2017. PMID: 28736082

7

Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.

Kranzbühler B, Salemi S, Mortezavi A, Sulser T, Eberli D. Kranzbühler B, et al. Prostate. 2019 Feb;79(2):206-214. doi: 10.1002/pros.23725. Epub 2018 Oct 21. Prostate. 2019. PMID: 30345525

8

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. Myung JK, et al. J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3. J Clin Invest. 2013. PMID: 23722902 Free PMC article.

9

Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor.

Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, Watt K, Tam T, Yang YC, Bañuelos CA, Williams DE, McEwan IJ, Wang Y, Sadar MD. Andersen RJ, et al. Cancer Cell. 2010 Jun 15;17(6):535-46. doi: 10.1016/j.ccr.2010.04.027. Cancer Cell. 2010. PMID: 20541699 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year